Guardant Health, Inc. provided earnings guidance for the full year 2022. For the period, the company expects revenue to be in the range of $440 million to $450 million, representing growth of 18% to 20% compared to full year 2021. This compares to previous full year 2022 revenue guidance of $460 million to $470 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.58 USD | +1.75% | +8.28% | -31.31% |
29/04 | Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating | MT |
22/04 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.31% | 2.23B | |
-18.16% | 11.03B | |
+58.43% | 3.5B | |
-14.31% | 2.16B | |
-26.61% | 1.54B | |
+34.35% | 1.12B | |
-3.28% | 737M | |
-22.75% | 477M | |
-40.20% | 411M | |
+17.30% | 342M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022